Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
benzoyl-o-cyano-Phe-Arg + H2O
benzoyl-o-cyano-Phe + Arg
-
-
-
?
Ala-Ser-His-Leu-Gly-Leu-Ala-Arg + H2O
Ala-Ser-His-Leu-Gly-Leu-Ala + Arg
-
reaction is much more efficient than reaction with EC 3.4.17.3
-
?
anaphylatoxin C3a + H2O
?
anaphylatoxin C5a + H2O
?
anisylazoformyl-Lys + H2O
anisylazoformic acid + Lys
-
-
-
?
Arg6-Leu5-enkephalin + H2O
Tyr-Gly-Gly-Phe-Leu + Arg
-
i.e. Tyr-Gly-Gly-Phe-Leu-Arg
-
-
?
Arg6-Met5-enkephalin + H2O
Tyr-Gly-Gly-Phe-Met + Arg
-
i.e. Tyr-Gly-Gly-Phe-Met-Arg
-
-
?
biotinyl-(epsilon-aminocaproic acid)-(epsilon-aminocaproic acid)-Gly-Leu-Met-Val-Gly-Gly-Val-Val-Arg-OH + H2O
biotinyl-(epsilon-aminocaproic acid)-(epsilon-aminocaproic acid)-Gly-Leu-Met-Val-Gly-Gly-Val-Val-OH + Arg
-
-
-
?
bradykinin + H2O
Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe + Arg
-
i.e. Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg
-
-
?
complement component C3a octapeptide + H2O
?
-
removal of terminal arginine, low activity
-
-
?
complement component C5a octapeptide + H2O
?
-
removal of terminal arginine
-
-
?
fibrin + H2O
fibrin + L-Lys
-
-
-
-
?
fibrin + H2O
fibrin + Lys
Fibrin, partially degraded + H2O
?
Fibrin, partially degraded + H2O
Fibrin, partially degraded + L-Lys + L-Arg
Glu-plasminogen + H2O
Glu + plasmin
-
-
-
-
?
hippuryl-Arg + H2O
hippuric acid + Arg
hippuryl-arginine + H2O
hippuric acid + L-arginine
-
substrate is used to measure the TAFI activation by plasmin
-
-
?
Hippuryl-L-Arg + H2O
Hippuric acid + L-Arg
hippuryl-L-arginine + H2O
hippuric acid + L-arginine
-
-
-
-
?
Hippuryl-L-argininic acid + H2O
Hippuric acid + argininic acid
-
-
-
-
?
Hippuryl-L-Lys + H2O
Hippuric acid + L-Lys
hippuryl-L-lysine + H2O
hippuric acid + L-lysine
-
-
-
-
?
His-Lys-Asp-Met-Gln-Leu-Gly-Arg + H2O
His-Lys-Asp-Met-Gln-Leu-Gly + Arg
Lys-plasminogen + H2O
Lys + plasmin
Lys6-Leu5-enkephalin + H2O
Tyr-Gly-Gly-Phe-Leu + Lys
-
i.e. Tyr-Gly-Gly-Phe-Leu-Lys
-
-
?
Lys6-Met5-enkephalin + H2O
Tyr-Gly-Gly-Phe-Met + Lys
-
i.e. Tyr-Gly-Gly-Phe-Met-Lys
-
-
?
N-benzoyl-2'-cyano-L-Phe-L-Arg + H2O
N-benzoyl-2'-cyano-L-Phe + L-Arg
-
selective CPU substrate
-
-
?
N-benzoyl-Gly-L-Arg + H2O
N-benzoyl-Gly + L-Arg
-
-
-
-
?
N-[3-(2-Furylacryloyl)]-L-Ala-L-Arg + H2O
N-[3-(2-Furylacryloyl)]-L-Ala + L-Arg
-
-
-
-
?
N-[3-(2-Furylacryloyl)]-L-Ala-L-Lys + H2O
N-[3-(2-Furylacryloyl)]-L-Ala + L-Lys
p-anisylazoformyl-L-arginine + H2O
p-anisylazoformic acid + L-arginine
-
substrate is used to measure the TAFI activation by thrombin and thrombin-thrombomodulin
-
-
?
[3-(2-furylacryloyl)]-L-alanyl-L-arginine + H2O
[3-(2-furylacryloyl)]-L-alanine + L-arginine
-
-
-
-
?
[3-(2-furylacryloyl)]-L-phenylalanyl-L-phenylalanine + H2O
[3-(2-furylacryloyl)]-L-phenylalanine + L-phenylalanine
-
-
-
-
?
additional information
?
-
anaphylatoxin C3a + H2O
?
-
-
-
-
?
anaphylatoxin C3a + H2O
?
-
inactivation of the inflammatory mediator
-
-
?
anaphylatoxin C5a + H2O
?
-
-
-
-
?
anaphylatoxin C5a + H2O
?
-
inactivation of the inflammatory mediator
-
-
?
fibrin + H2O
fibrin + Lys
-
anti-fibrinolytic activity
-
-
?
fibrin + H2O
fibrin + Lys
-
cleavage of C-terminal Lys, regulation, overview
the cleaved fibrin cannot be bound by plasminogen and the plasminogen activator in contrast to the uncleaved fibrin, fibrinolysis and plasmin regulation cycle involving the enzyme, overview
-
?
fibrin + H2O
fibrin + Lys
-
partially degraded fibrin in fibrin clots, cleavage of C-terminal Lys
-
-
?
fibrin + H2O
fibrin + Lys
-
cleavage of C-terminal Lys
-
-
?
fibrin + H2O
Lys + ?
-
-
-
?
fibrin + H2O
Lys + ?
-
attenuates clot lysis by removing lysine residues from a fibrin clot
-
?
Fibrin, partially degraded + H2O
?
-
-
-
-
?
Fibrin, partially degraded + H2O
?
-
the enzyme suppresses the ability of fibrin to catalyze plasminogen activation and thus delays clot lysis
-
-
?
Fibrin, partially degraded + H2O
?
-
inhibition of fibrinolysis
-
-
?
Fibrin, partially degraded + H2O
?
-
molecular connection between coagulation and fibrinolysis
-
-
?
Fibrin, partially degraded + H2O
Fibrin, partially degraded + L-Lys + L-Arg
-
-
-
?
Fibrin, partially degraded + H2O
Fibrin, partially degraded + L-Lys + L-Arg
-
-
-
?
Fibrin, partially degraded + H2O
Fibrin, partially degraded + L-Lys + L-Arg
-
-
-
?
Fibrin, partially degraded + H2O
Fibrin, partially degraded + L-Lys + L-Arg
-
-
-
-
?
hippuryl-Arg + H2O
hippuric acid + Arg
-
-
-
?
hippuryl-Arg + H2O
hippuric acid + Arg
-
-
-
?
hippuryl-Arg + H2O
hippuric acid + Arg
-
-
-
?
hippuryl-Arg + H2O
hippuric acid + Arg
-
-
-
?
hippuryl-Arg + H2O
hippuric acid + Arg
-
-
-
?
hippuryl-Arg + H2O
hippuric acid + Arg
-
-
-
-
?
Hippuryl-L-Arg + H2O
Hippuric acid + L-Arg
-
-
-
?
Hippuryl-L-Arg + H2O
Hippuric acid + L-Arg
-
-
-
-
?
Hippuryl-L-Lys + H2O
Hippuric acid + L-Lys
-
-
-
?
Hippuryl-L-Lys + H2O
Hippuric acid + L-Lys
-
-
-
-
?
His-Lys-Asp-Met-Gln-Leu-Gly-Arg + H2O
His-Lys-Asp-Met-Gln-Leu-Gly + Arg
-
i.e. C5a, reaction is much more efficient than reaction with EC 3.4.17.3
-
?
His-Lys-Asp-Met-Gln-Leu-Gly-Arg + H2O
His-Lys-Asp-Met-Gln-Leu-Gly + Arg
-
i.e. C5a, the enzyme significantly contributes to the inactivation of C5a, the most potent of the complement derived anaphylatoxins
-
?
Lys-plasminogen + H2O
Lys + plasmin
-
-
-
-
?
Lys-plasminogen + H2O
Lys + plasmin
-
preferred substrate
-
-
?
N-[3-(2-Furylacryloyl)]-L-Ala-L-Lys + H2O
N-[3-(2-Furylacryloyl)]-L-Ala + L-Lys
-
-
-
?
N-[3-(2-Furylacryloyl)]-L-Ala-L-Lys + H2O
N-[3-(2-Furylacryloyl)]-L-Ala + L-Lys
-
-
-
-
?
osteopontin + H2O
?
-
-
-
-
?
osteopontin + H2O
?
-
thrombin-cleaved substrate
-
-
?
additional information
?
-
the effects of the carboxypeptidase U system on the regulation of fibrinolysis is investigated and compared in four different in vitro models of fibrinolysis
-
-
?
additional information
?
-
-
no substrates are hippuryl-L-Phe, hippurylphenyllactic acid, hippuryl-Gly-Phe
-
-
?
additional information
?
-
-
removal of Lys or Arg from carboxy-terminus of peptides, specific for basic amino acids at carboxy-terminus
-
-
?
additional information
?
-
-
the activated enzyme shows anti-fibrinolytic and fibrin clot lysis activity
-
-
?
additional information
?
-
-
the enzyme circulates as inactive zymogen in the blood stream becoming activated upon blood clotting, the enzyme inhibits fibrinolysis by cleaving C-terminal lysine from the surface of partially degraded fibrin, which stimulates the tissue-type plasminogen activator-mediated conversion of plasminogen to plasmin, the enzyme might also be involved in regulation of inflammation and tissue repair, enzyme regulation overview
-
-
?
additional information
?
-
-
the enzyme down-regulates fibrinolysis by removing carboxy-terminal lysine residues, which are ligands for plasminogen and tissue-type plasminogen activator, from partially degraded fibrin, pharmacological profile and pathphysiological role of the enzyme in rat thrombolysis
-
-
?
additional information
?
-
-
the enzyme inhibits fibrinolysis
-
-
?
additional information
?
-
-
the enzyme inhibits fibrinolysis and has a distinct role in haemostasis and a possible risk factor for thrombotic disease involving the polymorphism at position 325, overview, the plasminogen activation system plays a role in enzyme regulation
-
-
?
additional information
?
-
-
the enzyme is involved and important in control of clot stability determined by clot formation and fibrinolysis, overview
-
-
?
additional information
?
-
-
the enzyme is involved in blood clot lysis
-
-
?
additional information
?
-
-
the enzyme is involved in the regulation of the coagulation and fibrinolytic systems preventing blood loss at sites of vessel wall damage and maintainthe fluidity of the blood in the body
-
-
?
additional information
?
-
-
the enzyme is partially accountable for the antifibrinolytic activity in amniotic fluid
-
-
?
additional information
?
-
-
the enzyme might be the primary in vivo regulator of complement component C5a-mediated inflammation in the circulation, the enzyme cleaves terminal lysine from the surface of fibrin clots preventing the binding and activation of plasminogen and inhibiting whole blood clot lysis
-
-
?
additional information
?
-
-
the enzyme, activated by thrombin, protects the fibrin clot against lysis, altered enzyme activity is involved in bleeding and thrombotic disorders, the enzyme is involved in wound healing and inflammation, overview
-
-
?
additional information
?
-
-
thrombin activatable fibrinolysis inhibitor and its fibrinolytic effect in normal pregnancy
-
-
?
additional information
?
-
-
thrombin activatable fibrinolysis inhibitor, TAFI, plays a role in the delicate balance between coagulation and fibrinolysis, the stability of the fibrin clot, inflammation, thrombosis, and in Behcets disease, vascular involvement pattern in patients, overview
-
-
?
additional information
?
-
-
enzyme assay using a specific chromogenic dipeptide substrate
-
-
?
additional information
?
-
-
the enzyme binds alpha2-macroglobulin and pregnancy zone protein, which does not inhibit the enzyme
-
-
?
additional information
?
-
-
the enzyme binds to plasminogen and fibrinogen
-
-
?
additional information
?
-
-
TFAI binds heparin
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Abortion, Habitual
Levels of thrombin-activatable fibrinolysis inhibitor and platelet-activating factor in recurrent pregnancy loss patients.
Abortion, Habitual
Reduced plasma fibrinolytic potential in patients with recurrent implantation failure after IVF and embryo transfer.
Abortion, Habitual
Thrombin activatable fibrinolysis inhibitor (TAFI) is not associated with recurrent miscarriage.
Abortion, Habitual
Thrombin activatable fibrinolysis inhibitor and clot lysis time in women with recurrent miscarriage associated with the antiphospholipid syndrome.
Abortion, Spontaneous
Relationship Between Polymorphism of Thrombin-Activatable Fibrinolysis Inhibitor Gene +1040C/T and a Cohort of Chinese Women With Recurrent Spontaneous Abortion.
Abortion, Spontaneous
The prevalence of combined vascular endothelial growth factor, endothelial nitric oxide synthase and thrombin-activatable fibrinolysis inhibitor genetic polymorphisms among Egyptian patients with recurrent spontaneous abortion.
Abortion, Spontaneous
Thrombin-Activatable Fibrinolysis Inhibitor Gene Polymorphism (TAFI1040C/T) in Women With Recurrent Spontaneous Abortion.
Activated Protein C Resistance
Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation.
Acute Coronary Syndrome
Comparison of two immunochemical assays for measuring thrombin-activatable fibrinolysis inhibitor concentration with a functional assay in patients with acute coronary syndrome.
Acute Coronary Syndrome
Reduced thrombin activatable fibrinolysis inhibitor and enhanced proinflammatory cytokines in acute coronary syndrome.
Acute Coronary Syndrome
Thrombin-activatable fibrinolysis inhibitor genetic polymorphisms as markers of the type of acute coronary syndrome.
Acute Lung Injury
Thrombin-Activatable Fibrinolysis Inhibitor Protects against Acute Lung Injury by Inhibiting the Complement System.
Adenocarcinoma
Increased circulating levels of thrombin-activatable fibrinolysis inhibitor in lung cancer patients.
Amyloidosis
Higher thrombin activatable fibrinolysis inhibitor levels are associated with inflammation in attack-free familial Mediterranean fever patients.
Angina, Stable
Plasma procarboxypeptidase U in men with symptomatic coronary artery disease.
Angina, Stable
Thrombin activatable fibrinolysis inhibitor (TAFI) in stable angina pectoris patients undergoing coronary artery bypass grafting (CABG).
Angina, Unstable
Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris.
Angioedema
Angioedema. A review on the acquired, allergic or non-allergic, and the hereditary forms.
Antiphospholipid Syndrome
Clot lysis time and thrombin activatable fibrinolysis inhibitor in severe preeclampsia with or without associated antiphospholipid antibodies.
Antiphospholipid Syndrome
Increase in plasma thrombin-activatable fibrinolysis inhibitor may not contribute to thrombotic tendency in antiphospholipid syndrome because of inhibitory potential of antiphospholipid antibodies toward TAFI activation.
Antiphospholipid Syndrome
Thrombin activatable fibrinolysis inhibitor (TAFI) - A possible link between coagulation and complement activation in the antiphospholipid syndrome (APS).
Antiphospholipid Syndrome
Thrombin activatable fibrinolysis inhibitor and clot lysis time in pregnant patients with antiphospholipid syndrome: relationship with pregnancy outcome and thrombosis.
Antiphospholipid Syndrome
Thrombin activatable fibrinolysis inhibitor and clot lysis time in women with recurrent miscarriage associated with the antiphospholipid syndrome.
Aortic Aneurysm, Abdominal
Activity of thrombin-activatable fibrinolysis inhibitor in the plasma of patients with abdominal aortic aneurysm.
Aortic Aneurysm, Abdominal
Enhanced Abdominal Aortic Aneurysm Formation in Thrombin-Activatable Procarboxypeptidase B-Deficient Mice.
Aortic Aneurysm, Abdominal
Thrombin-activatable fibrinolysis inhibitor in human abdominal aortic aneurysm disease.
Arthritis
Plasma carboxypeptidase B downregulates inflammatory responses in autoimmune arthritis.
Arthritis, Rheumatoid
An arginine carboxypeptidase generated during coagulation is diminished or absent in patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Assessment of hemostatic disturbances in women with established rheumatoid arthritis.
Arthritis, Rheumatoid
Thrombin-activatable fibrinolysis inhibitor and its relation with inflammation in rheumatoid arthritis.
Asthma
Role of Thrombin-Activatable Fibrinolysis Inhibitor in Allergic Bronchial Asthma.
Asthma
Up-regulation of the extrinsic coagulation pathway in acute asthma--a case study.
Asthma
[Thrombin activatable fibrinolysis inhibitor (TAFI) in allergic asthma patients]
Atherosclerosis
Plasma Thrombin-Activatable Fibrinolysis Inhibitor Levels are not Associated With Glucose Intolerance and Subclinical Atherosclerosis in Women With Previous Gestational Diabetes.
Atherosclerosis
Thrombin activatable fibrinolysis inhibitor (TAFI) and markers of endothelial cell injury in dialyzed patients with diabetic nephropathy.
Atypical Hemolytic Uremic Syndrome
Thrombomodulin mutations in atypical hemolytic-uremic syndrome.
Bacterial Infections
EF6265, a novel inhibitor of activated thrombin-activatable fibrinolysis inhibitor, protects against sepsis-induced organ dysfunction in rats.
beta-Thalassemia
Thrombin Activable Fibrinolysis Inhibitor in Beta Thalassemia.
beta-Thalassemia
Thrombin activatable fibrinolysis inhibitor (TAFI): relationship to hemostatic alteration in patients with beta-thalassemia.
Breast Neoplasms
Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis.
Breast Neoplasms
Activated thrombin-activatable fibrinolysis inhibitor attenuates the angiogenic potential of endothelial cells: potential relevance to the breast tumour microenvironment.
Breast Neoplasms
Data supporting the structural and functional characterization of Thrombin-Activatable Fibrinolysis Inhibitor in breast cancer.
Breast Neoplasms
Plasma thrombin-activatable fibrinolysis inhibitor levels and its Thr325Ile polymorphism in breast cancer.
Breast Neoplasms
Thrombin-activatable fibrinolysis inhibitor in breast cancer patients.
Breast Neoplasms
Thrombin-activatable fibrinolysis inhibitor Thr325Ile polymorphism and plasma level in breast cancer: A pilot study.
carboxypeptidase u deficiency
Carboxypeptidase B2 deficiency reveals opposite effects of complement C3a and C5a in a murine polymicrobial sepsis model.
carboxypeptidase u deficiency
Immune complex-mediated glomerulonephritis is ameliorated by thrombin-activatable fibrinolysis inhibitor deficiency.
carboxypeptidase u deficiency
Procarboxypeptidase R deficiency causes increased lethality in concanavalin A-induced hepatitis in female mice.
carboxypeptidase u deficiency
Thrombin-activatable fibrinolysis inhibitor deficiency attenuates bleomycin-induced lung fibrosis.
carboxypeptidase u deficiency
Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis.
Carcinogenesis
The 1040C/T polymorphism influencing thermal stability and activity of thrombin activatable fibrinolysis inhibitor is associated with risk for oral cancer.
Carcinoma
Increased circulating levels of thrombin-activatable fibrinolysis inhibitor in lung cancer patients.
Carcinoma, Hepatocellular
Identification of human thrombin-activatable fibrinolysis inhibitor in vascular and inflammatory cells.
Carcinoma, Hepatocellular
Molecular Mechanism Underlying the Suppression of CPB2 Expression Caused by Persistent Hepatitis C Virus RNA Replication.
Carcinoma, Hepatocellular
PI3-Kinase Inhibitor LY294002 Repressed the Expression of Thrombin-Activatable Fibrinolysis Inhibitor in Human Hepatoma HepG2 Cells.
Carcinoma, Small Cell
Increased circulating levels of thrombin-activatable fibrinolysis inhibitor in lung cancer patients.
Carcinoma, Squamous Cell
Increased circulating levels of thrombin-activatable fibrinolysis inhibitor in lung cancer patients.
Cardiovascular Diseases
A new functional assay of thrombin activatable fibrinolysis inhibitor.
Cardiovascular Diseases
Clots, kinins and coronaries.
Cardiovascular Diseases
Genetic variations in the thrombin-activatable fibrinolysis inhibitor gene and risk of cardiovascular disease: a systematic review and meta-analysis.
Cardiovascular Diseases
Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography.
Cerebral Infarction
Association between polymorphisms in the flanking region of the TAFI gene and atherosclerotic cerebral infarction in a Chinese population.
coagulation factor xia deficiency
Is resistance futile? The role of activated thrombin-activatable fibrinolysis inhibitor resistance in bleeding in factor XI deficiency.
coagulation factor xia deficiency
Perioperative use of modified thrombelastography in factor XI deficiency: a helpful method to assess drug effects.
coagulation factor xia deficiency
Reduced fibrinolytic resistance in patients with factor XI deficiency. Evidence of a thrombin-independent impairment of the thrombin-activatable fibrinolysis inhibitor pathway.
Colitis, Ulcerative
Plasma Thrombin-activatable Fibrinolysis Inhibitor Levels Correlate with the Disease Activity of Ulcerative Colitis.
Corneal Neovascularization
The role of the fibrinolytic system in corneal angiogenesis.
Coronary Artery Disease
Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study.
Coronary Artery Disease
Changes in ADMA and TAFI levels after stenting in coronary artery disease patients.
Coronary Artery Disease
Fibrinolytic status in acute coronary syndromes: evidence of differences in relation to clinical features and pathophysiological pathways.
Coronary Artery Disease
Plasma procarboxypeptidase U in men with symptomatic coronary artery disease.
Coronary Artery Disease
Risk of acute coronary artery disease associated with functional thrombin activatable fibrinolysis inhibitor plasma level.
Coronary Artery Disease
Thrombin activatable fibrinolysis inhibitor (TAFI) in stable angina pectoris patients undergoing coronary artery bypass grafting (CABG).
Coronary Artery Disease
Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography.
Coronary Disease
Selective modulation of thrombin-activatable fibrinolysis inhibitor (TAFI) activation by thrombin or the thrombin-thrombomodulin complex using TAFI-derived peptides.
Coronary Disease
TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: the PRIME Study.
Coronary Disease
[Study on the association of thrombin activatable fibrinolysis inhibitor and the Thr325Ile and Thr147Ala polymorphisms of its encoding gene CPB2 in patients with coronary heart disease]
Coronary Restenosis
Changes in ADMA and TAFI levels after stenting in coronary artery disease patients.
Coronary Restenosis
Thrombin-activatable fibrinolysis inhibitor (TAFI): a novel predictor of angiographic coronary restenosis.
COVID-19
Studies on hemostasis in COVID-19 deserve careful reporting of the laboratory methods, their significance and their limitations.
Cushing Syndrome
Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels.
Diabetes Mellitus
Effect of single nucleotide polymorphism in thrombin-activatable fibrinolysis inhibitor on the risk of diabetic macrovascular disease.
Diabetes Mellitus
Plasma thrombin-activatable fibrinolysis inhibitor levels in children and adolescents with type 1 diabetes mellitus: possible relation to diabetic microvascular complications.
Diabetes Mellitus
Polycystic ovary syndrome: clinical and laboratory variables related to new phenotypes using machine-learning models.
Diabetes Mellitus
Predisposing factors to post-operative adhesion development.
Diabetes Mellitus
Thrombin activatable fibrinolysis inhibitor and hemostatic changes in patients with type I diabetes mellitus with and without microvascular complications.
Diabetes Mellitus, Type 1
Plasma thrombin-activatable fibrinolysis inhibitor levels in children and adolescents with type 1 diabetes mellitus: possible relation to diabetic microvascular complications.
Diabetes Mellitus, Type 1
Thrombin-activatable fibrinolysis inhibitor activity and global fibrinolytic capacity in Type 1 diabetes: evidence for normal fibrinolytic state.
Diabetes Mellitus, Type 2
Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor.
Diabetes, Gestational
Gestational diabetes has no additional effect on plasma thrombin-activatable fibrinolysis inhibitor antigen levels beyond pregnancy.
Diabetes, Gestational
Levels of thrombin activatable fibrinolysis inhibitor in gestational diabetes mellitus.
Diabetes, Gestational
Plasma Thrombin-Activatable Fibrinolysis Inhibitor Levels are not Associated With Glucose Intolerance and Subclinical Atherosclerosis in Women With Previous Gestational Diabetes.
Diabetic Foot
Plasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels in diabetic foot ulcers.
Diabetic Nephropathies
Adiponectin is related to CD146, a novel marker of endothelial cell activation/injury in chronic renal failure and peritoneally dialyzed patients.
Diabetic Nephropathies
Genetic variation in thrombin-activatable fibrinolysis inhibitor is associated with the risk of diabetic nephropathy.
Diabetic Nephropathies
Thrombin activatable fibrinolysis inhibitor (TAFI) and markers of endothelial cell injury in dialyzed patients with diabetic nephropathy.
Disseminated Intravascular Coagulation
A low TAFI activity and insufficient activation of fibrinolysis by both plasmin and neutrophil elastase promote organ dysfunction in disseminated intravascular coagulation associated with sepsis.
Disseminated Intravascular Coagulation
Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation.
Disseminated Intravascular Coagulation
Disseminated intravascular coagulation at an early phase of trauma is associated with consumption coagulopathy and excessive fibrinolysis both by plasmin and neutrophil elastase.
Disseminated Intravascular Coagulation
Plasma antigen levels of thrombin-activatable fibrinolysis inhibitor did not differ in patients with or without disseminated intravascular coagulation.
Disseminated Intravascular Coagulation
Plasma Levels of Plasminogen Activator Inhibitor-1 (PAI-1) and Thrombin Activatable Fibrinolysis Inhibitor (TAFI) in Patients with Disseminated Intravascular Coagulation (DIC).
Dyslipidemias
Thrombin-activatable fibrinolysis inhibitor (TAFI) levels and its polymorphism rs3742264 are associated with dyslipidemia in a cohort of Brazilian subjects.
Dyslipidemias
Thrombin-activatable fibrinolysis inhibitor in kidney transplant recipient with dyslipidemia.
Endometriosis
Genetic Variants in Fibrinolytic System-Related Genes in Infertile Women With and Without Endometriosis.
Endotoxemia
Inflammation and thrombin generation cause increased thrombin activatable fibrinolysis inhibitor levels in experimental human endotoxemia.
Factor XI Deficiency
Is resistance futile? The role of activated thrombin-activatable fibrinolysis inhibitor resistance in bleeding in factor XI deficiency.
Factor XI Deficiency
Perioperative use of modified thrombelastography in factor XI deficiency: a helpful method to assess drug effects.
Factor XI Deficiency
Reduced fibrinolytic resistance in patients with factor XI deficiency. Evidence of a thrombin-independent impairment of the thrombin-activatable fibrinolysis inhibitor pathway.
Factor XIII Deficiency
Polymorphism of thrombin-activatable fibrinolysis inhibitor and risk of intracranial haemorrhage in factor XIII deficiency.
Familial Mediterranean Fever
Higher thrombin activatable fibrinolysis inhibitor levels are associated with inflammation in attack-free familial Mediterranean fever patients.
Fatty Liver
Plasminogen activator inhibitor-1 and thrombin activatable fibrinolysis inhibitor levels in non-alcoholic steatohepatitis.
Foot Ulcer
Plasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels in diabetic foot ulcers.
Glioblastoma
Thrombin-cleaved fragments of osteopontin are overexpressed in malignant glial tumors and provide a molecular niche with survival advantage.
Glomerulonephritis
EF6265, a novel plasma carboxypeptidase B inhibitor, protects against renal dysfunction in rat thrombotic glomerulonephritis through enhancing fibrinolysis.
Glomerulonephritis
Immune complex-mediated glomerulonephritis is ameliorated by thrombin-activatable fibrinolysis inhibitor deficiency.
Glucose Intolerance
Plasma Thrombin-Activatable Fibrinolysis Inhibitor Levels are not Associated With Glucose Intolerance and Subclinical Atherosclerosis in Women With Previous Gestational Diabetes.
Hashimoto Disease
The effect of hormone replacement treatment on thrombin-activatable fibrinolysis inhibitor activity levels in patients with Hashimoto thyroiditis.
Heart Failure
A Prothrombotic State in Patients With a History of Left Ventricular Thrombus.
Hemophilia A
Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease?
Hemophilia A
Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A.
Hemophilia A
On-demand but not prophylactic treatment with FVIII concentrate increase thrombin activatable fibrinolysis inhibitor activation in severe haemophilia A patients.
Hemophilia A
Overall haemostatic potential can be used for estimation of thrombin-activatable fibrinolysis inhibitor-dependent fibrinolysis in vivo and for possible follow-up of recombinant factor VIIa treatment in patients with inhibitors to factor VIII.
Hemophilia A
Platelet factor 4 inhibits thrombomodulin-dependent activation of thrombin-activatable fibrinolysis inhibitor (TAFI) by thrombin.
Hemophilia A
TAFI deficiency causes maladaptive vascular remodeling after hemophilic joint bleeding.
Hemophilia A
TAFI made stickier.
Hemophilia A
Thrombin activatable fibrinolysis inhibitor activation and bleeding in haemophilia A.
Hemophilia A
Thrombin activatable fibrinolysis inhibitor pathway alterations correlate with bleeding phenotype in patients with severe hemophilia A.
Hemophilia A
Total thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and pro-TAFI in patients with haemophilia A.
Hemophilia B
Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease?
Hemorrhagic Fever, Crimean
Plasma activity of thrombin activatable fibrinolysis inhibitor in Crimean-Congo hemorrhagic fever.
Hepatitis
Hepatitis induced by an IgM monoclonal antibody against procarboxypeptidase R.
Hepatitis
Procarboxypeptidase R deficiency causes increased lethality in concanavalin A-induced hepatitis in female mice.
Hyperalgesia
Thrombomodulin alfa prevents oxaliplatin-induced neuropathic symptoms through activation of thrombin-activatable fibrinolysis inhibitor and protein C without affecting anti-tumor activity.
Hypercholesterolemia
Effect of Statin Therapy on the Carboxypeptidase U (CPU, TAFIa, CPB2) System in Patients With Hyperlipidemia: A Proof-of-concept Observational Study.
Hypercholesterolemia
Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor.
Hyperglycemia
Predisposing factors to post-operative adhesion development.
Hyperlipidemias
Development of ELISAs measuring the extent of TAFI activation.
Hyperlipidemias
Effect of Statin Therapy on the Carboxypeptidase U (CPU, TAFIa, CPB2) System in Patients With Hyperlipidemia: A Proof-of-concept Observational Study.
Hyperparathyroidism, Primary
Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism.
Hypertension
The relationship among TAFI, t-PA, PAI-1 and F1?+?2 in type 2 diabetic patients with normoalbuminuria and microalbuminuria.
Hypertension
Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with essential arterial hypertension.
Hypertension, Pregnancy-Induced
Thrombin activatable fibrinolysis inhibitor in preeclampsia and gestational hypertension throughout the gestation.
Hypertension, Pulmonary
Pulmonary hypertension is ameliorated in mice deficient in thrombin-activatable fibrinolysis inhibitor.
Hypertension, Pulmonary
Thrombin-Activatable Fibrinolysis Inhibitor in Chronic Thromboembolic Pulmonary Hypertension.
Hyperthyroidism
Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hyperthyroidism.
Hyperthyroidism
Thrombin activatable fibrinolysis inhibitor antigen levels are inversely correlated with plasminogen activator inhibitor-1 antigen levels in hyperthyroid patients.
Hypotension
Elevated bradykinin and decreased carboxypeptidase R as a cause of hypotension during tryptophan column immunoabsorption therapy.
Hypothyroidism
Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor and thrombomodulin levels in children with hypothyroidism.
Hypothyroidism
Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hypothyroidism.
Hypothyroidism
Thrombin-activatable fibrinolysis inhibitor in hypothyroidism and hyperthyroxinaemia.
Infections
Thrombin activatable fibrinolysis inhibitor: not just an inhibitor of fibrinolysis.
Inflammatory Bowel Diseases
Activated thrombin activatable fibrinolysis inhibitor (TAFIa) is associated with inflammatory markers in inflammatory bowel diseases TAFIa level in patients with IBD.
Inflammatory Bowel Diseases
Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases.
Inflammatory Bowel Diseases
Plasma levels of thrombin activatable fibrinolysis inhibitor antigen in active and inactive inflammatory bowel disease.
Inflammatory Bowel Diseases
Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease.
Inflammatory Breast Neoplasms
IL-10 correlates with the expression of carboxypeptidase B2 and lymphovascular invasion in inflammatory breast cancer: The potential role of tumor infiltrated macrophages.
Influenza, Human
Characterization of the carboxypeptidase involved in the proteolytic cleavage of the influenza haemagglutinin.
Insulin Resistance
Increased plasma thrombin-activatable fibrinolysis inhibitor levels in young obese women with polycystic ovary syndrome.
Insulin Resistance
Insulin resistance is associated with increased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients.
Insulin Resistance
Is There a Tendency for Thrombosis in Gestational Diabetes Mellitus?
Insulin Resistance
Plasma Thrombin-Activatable Fibrinolysis Inhibitor Levels are not Associated With Glucose Intolerance and Subclinical Atherosclerosis in Women With Previous Gestational Diabetes.
Insulin Resistance
Weak and non-independent association between plasma TAFI antigen levels and the insulin resistance syndrome.
Intracranial Hemorrhages
Carboxypeptidase U (TAFIa) decreases the efficacy of thrombolytic therapy in ischemic stroke patients.
Ischemic Stroke
Carboxypeptidase U (TAFIa) activity is induced in vivo in ischemic stroke patients receiving thrombolytic therapy.
Ischemic Stroke
Carboxypeptidase U (TAFIa) decreases the efficacy of thrombolytic therapy in ischemic stroke patients.
Ischemic Stroke
Changes in Activated Thrombin-Activatable Fibrinolysis Inhibitor Levels Following Thrombolytic Therapy in Ischemic Stroke Patients Correlate with Clinical Outcome.
Ischemic Stroke
High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke.
Ischemic Stroke
Influence of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 gene polymorphisms on tissue-type plasminogen activator-induced recanalization in ischemic stroke patients.
Ischemic Stroke
Inhibition of Thrombin-Activatable Fibrinolysis Inhibitor and Plasminogen Activator Inhibitor-1 Reduces Ischemic Brain Damage in Mice.
Ischemic Stroke
Procarboxypeptidase U (proCPU, TAFI, proCPB2) in cerebrospinal fluid during ischemic stroke is associated with stroke progression, outcome and blood-brain barrier dysfunction.
Ischemic Stroke
Risk of ischemic stroke associated with functional thrombin-activatable fibrinolysis inhibitor plasma levels.
Ischemic Stroke
Safety and Pharmacokinetics of DS-1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin.
Ischemic Stroke
Selective inhibition of carboxypeptidase U may reduce microvascular thrombosis in rat experimental stroke.
Ischemic Stroke
The decrease in procarboxypeptidase U (TAFI) concentration in acute ischemic stroke correlates with stroke severity, evolution and outcome.
Ischemic Stroke
Thrombin activatable fibrinolysis inhibitor activation peptide shows association with all major subtypes of ischemic stroke and with TAFI gene variation.
Ischemic Stroke
Thrombin activatable fibrinolysis inhibitor and its relationship to fibrinolysis and inflammation during the acute and convalescent phase of ischemic stroke.
Ischemic Stroke
Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischemic stroke.
Ischemic Stroke
Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice are susceptible to intracerebral thrombosis and ischemic stroke.
Kidney Failure, Chronic
Adiponectin is related to CD146, a novel marker of endothelial cell activation/injury in chronic renal failure and peritoneally dialyzed patients.
Kidney Failure, Chronic
Serum procarboxypeptidase B, amylase and lipase in chronic renal failure.
Kidney Failure, Chronic
Thrombin activatable fibrinolysis inhibitor (TAFI) and markers of endothelial cell injury in dialyzed patients with diabetic nephropathy.
Liver Diseases
Low levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with chronic liver disease.
Lung Diseases, Interstitial
Thrombin-activatable fibrinolysis inhibitor and protein C inhibitor in interstitial lung disease.
Lung Neoplasms
Increased circulating levels of thrombin-activatable fibrinolysis inhibitor in lung cancer patients.
Lung Neoplasms
Thrombin-activatable fibrinolysis inhibitor levels in patients with non-small-cell lung cancer.
Lupus Erythematosus, Systemic
Thrombin-activatable fibrinolysis inhibitor and activated factor XII in patients with systemic lupus erythematosus.
Meningitis, Pneumococcal
Thrombin-activatable fibrinolysis inhibitor influences disease severity in humans and mice with pneumococcal meningitis.
Meningococcal Infections
A functional single nucleotide polymorphism in the thrombin-activatable fibrinolysis inhibitor (TAFI) gene associates with outcome of meningococcal disease.
Meningococcal Infections
Thrombin activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children.
Metabolic Syndrome
Fenofibrate improves endothelial function and decreases thrombin-activatable fibrinolysis inhibitor concentration in metabolic syndrome.
Metabolic Syndrome
Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor.
Metabolic Syndrome
Predisposing factors to post-operative adhesion development.
Mouth Neoplasms
The 1040C/T polymorphism influencing thermal stability and activity of thrombin activatable fibrinolysis inhibitor is associated with risk for oral cancer.
Multiple Myeloma
Serum thrombin activatable fibrinolysis inhibitor levels in patients with newly diagnosed multiple myeloma.
Muscle Cramp
Knowledge, attitude and practice towards anthrax in northern Ethiopia: a mixed approach study.
Myocardial Infarction
Crystal structures of potent thiol-based inhibitors bound to carboxypeptidase B.
Myocardial Infarction
Fibrinolytic status in acute coronary syndromes: evidence of differences in relation to clinical features and pathophysiological pathways.
Myocardial Infarction
Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men.
Myocardial Infarction
Plasma levels of carboxypeptidase U (CPU, CPB2 or TAFIa) are elevated in patients with acute myocardial infarction.
Myocardial Infarction
Plasma TAFI and soluble CD40 ligand do not predict reperfusion following thrombolysis for acute myocardial infarction.
Myocardial Infarction
Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe.
Myocardial Infarction
Plasma thrombin-activatable fibrinolysis inhibitor levels and Thr325Ile polymorphism as a risk marker of myocardial infarction in Egyptian patients.
Myocardial Infarction
Structures of potent selective peptide mimetics bound to carboxypeptidase B.
Myocardial Infarction
Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system.
Myocardial Infarction
[Prognosis value of thrombin activatable fibrinolysis inhibitor concentration and C1040T polymorphism in acute myocardial infarction treated with fibrinolysis.]
Nasal Polyps
Increased thrombin-activatable fibrinolysis inhibitor levels in patients with chronic rhinosinusitis with nasal polyps.
Neoplasm Metastasis
Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis.
Neoplasms
Biochemical analysis of secretory proteins synthesized by normal rat pancreas and by pancreatic acinar tumor cells.
Neoplasms
Comparison of secretory protein profiles in developing rat pancreatic rudiments and rat acinar tumor cells.
Neoplasms
Endothelial function and novel adhesion molecule CD44 in kidney allograft recipients.
Neoplasms
High incidence of tumors in diabetic thrombin activatable fibrinolysis inhibitor and apolipoprotein E double deficient mice.
Neoplasms
IL-10 correlates with the expression of carboxypeptidase B2 and lymphovascular invasion in inflammatory breast cancer: The potential role of tumor infiltrated macrophages.
Neoplasms
Increased circulating levels of thrombin-activatable fibrinolysis inhibitor in lung cancer patients.
Neoplasms
Predisposing factors to post-operative adhesion development.
Neoplasms
Thrombin Activatable Fibrinolysis inhibitor in Cancer Patients with and without Venous Thromboembolism.
Neoplasms
Thrombomodulin suppresses invasiveness of HT1080 tumor cells by reducing plasminogen activation on the cell surface through activation of thrombin-activatable fibrinolysis inhibitor.
Nephrotic Syndrome
Markers of endothelial cell injury and thrombin activatable fibrinolysis inhibitor in nephrotic syndrome.
Obesity
Decrements in the thrombin activatable fibrinolysis inhibitor (TAFI) levels in association with orlistat treatment in obesity.
Obesity
Increased plasma thrombin-activatable fibrinolysis inhibitor levels in young obese women with polycystic ovary syndrome.
Obesity
Predisposing factors to post-operative adhesion development.
Obesity
Reductions in plasmin inhibitor and fibrinogen predict the improved fibrin clot lysis 6?months after obesity surgery.
Obesity
[The role of thrombin activatable fibrinolysis inhibitor in disturbances of fibrinolytic system in obesity]
Overweight
Increased plasma thrombin-activatable fibrinolysis inhibitor levels in young obese women with polycystic ovary syndrome.
Pancreatitis
A study on the activation peptide released from procarboxypeptidase B (CAPAP) and anionic trypsinogen in patients with acute abdominal disorders of non-pancreatic origin.
Pancreatitis
Activation peptide of carboxypeptidase B in serum and urine in acute pancreatitis.
Pancreatitis
Active carboxypeptidase B is present in free form in serum from patients with acute pancreatitis.
Pancreatitis
Comparative analysis of the sequences and three-dimensional models of human procarboxypeptidases A1, A2 and B.
Pancreatitis
Isolation of a cDNA encoding a human serum marker for acute pancreatitis. Identification of pancreas-specific protein as pancreatic procarboxypeptidase B.
Pancreatitis
Laboratory markers of severe acute pancreatitis.
Pancreatitis
Monocyte Chemoattractant Protein 1, Active Carboxypeptidase B and CAPAP at Hospital Admission Are Predictive Markers for Severe Acute Pancreatitis.
Pancreatitis
Plasma thrombin-activatable fibrinolysis inhibitor as an indicator of inflammation and disease severity in acute pancreatitis.
Pancreatitis
Protease Activation, Pancreatic Leakage, and Inflammation in Acute Pancreatitis: Differences between Mild and Severe Cases and Changes over the First Three Days.
Pancreatitis
Radioimmunoassay of active pancreatic enzymes in sera from patients with acute pancreatitis. I. Active carboxypeptidase B.
Pancreatitis
Serum levels of procarboxypeptidase B and its activation peptide in patients with acute pancreatitis and non-pancreatic diseases.
Pancreatitis
Serum procarboxypeptidase B, amylase and lipase in chronic renal failure.
Pancreatitis
The clinical value of human pancreas-specific protein procarboxypeptidase B as an indicator of necrosis in acute pancreatitis: comparison to CRP and LDH.
Pancreatitis
Thrombin activatable fibrinolysis inhibitor as an indicator of the severity of acute pancreatitis.
Pancreatitis, Acute Necrotizing
Serum levels of procarboxypeptidase B and its activation peptide in patients with acute pancreatitis and non-pancreatic diseases.
Peripheral Arterial Disease
High thrombin activatable fibrinolysis inhibitor levels are associated with an increased risk of premature peripheral arterial disease.
Polycystic Ovary Syndrome
Effect of android fat distribution on thrombin-activatable fibrinolysis inhibitor levels in women with polycystic ovary syndrome.
Polycystic Ovary Syndrome
Elevated thrombin activatable fibrinolysis inhibitor levels in women with polycystic ovary syndrome.
Polycystic Ovary Syndrome
Increased plasma thrombin-activatable fibrinolysis inhibitor levels in young obese women with polycystic ovary syndrome.
Polycystic Ovary Syndrome
Increased thrombin-activatable fibrinolysis inhibitor antigen levels as a clue for prothrombotic state in polycystic ovary syndrome.
Polycystic Ovary Syndrome
Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with polycystic ovary syndrome.
Polycystic Ovary Syndrome
Thrombin-Activatable Fibrinolysis Inhibitor and Cardiovascular Risk Factors in Polycystic Ovary Syndrome.
Postthrombotic Syndrome
Novel antithrombotic strategies for treatment of venous thromboembolism.
Pre-Eclampsia
Association between genotype and plasma levels of thrombin-activated fibrinolysis inhibitor (TAFI) in the development of preeclampsia.
Pre-Eclampsia
Clot lysis time and thrombin activatable fibrinolysis inhibitor in severe preeclampsia with or without associated antiphospholipid antibodies.
Pre-Eclampsia
Does thrombin activatable fibrinolysis inhibitor (TAFI) contribute to impairment of fibrinolysis in patients with preeclampsia and/or intrauterine fetal growth retardation?
Pre-Eclampsia
Fibrinolysis parameters in Sudanese women with severe preeclampsia.
Pre-Eclampsia
Preeclampsia and its interaction with common variants in thrombophilia genes.
Pre-Eclampsia
Thrombin activatable fibrinolysis inhibitor in preeclampsia and gestational hypertension throughout the gestation.
protein-glutamine gamma-glutamyltransferase deficiency
Polymorphism of thrombin-activatable fibrinolysis inhibitor and risk of intracranial haemorrhage in factor XIII deficiency.
Pulmonary Embolism
Association of Thrombin-Activatable Fibrinolysis Inhibitor with Acute Pulmonary Embolism.
Pulmonary Embolism
Phosphinanes and Azaphosphinanes as Potent and Selective Inhibitors of Activated Thrombin-Activatable Fibrinolysis Inhibitor (TAFIa).
Pulmonary Embolism
Role of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with acute pulmonary embolism.
Pulmonary Embolism
S62798, a potent TAFIa inhibitor, accelerates endogenous fibrinolysis in a murine model of pulmonary thromboembolism.
Pulmonary Embolism
[Spontaneous fibrinolysis and possibilities of its acceleration in pulmonary embolism].
Respiratory Distress Syndrome
Thrombin activatable fibrinolysis inhibitor activity, thrombin-antithrombin complex and D-dimer levels in preterm neonates with early respiratory distress syndrome.
Retinal Vein Occlusion
Assessment of the role of thrombin activatable fibrinolysis inhibitor in retinal vein occlusion.
Rhinitis, Allergic
Increased Thrombin-Activatable Fibrinolysis Inhibitor in Response to Sublingual Immunotherapy for Allergic Rhinitis.
Sepsis
Carboxypeptidase B2 deficiency reveals opposite effects of complement C3a and C5a in a murine polymicrobial sepsis model.
Sepsis
EF6265, a novel inhibitor of activated thrombin-activatable fibrinolysis inhibitor, protects against sepsis-induced organ dysfunction in rats.
Sepsis
Elevated levels of activated and inactivated thrombin-activatable fibrinolysis inhibitor in patients with sepsis.
Sepsis
Plasma thrombin activatable fibrinolysis inhibitor and tissue factor pathway inhibitor changes following sepsis.
Sepsis
Platelet Drop and Fibrinolytic Shutdown in Patients With Sepsis.
Sepsis
Thrombin activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children.
Sepsis
Thrombin-activatable fibrinolysis inhibitor is activated in vivo in a baboon model of Escherichia coli induced sepsis.
ST Elevation Myocardial Infarction
Fibrinolytic status in acute coronary syndromes: evidence of differences in relation to clinical features and pathophysiological pathways.
Stomach Neoplasms
Is there any role of thrombin activatable fibrinolysis inhibitor in the development of a hypercoagulable state in gastric cancer.
Stomach Neoplasms
Thrombin activatable fibrinolysis inhibitor and thrombin-antithrombin-III-complex levels in patients with gastric cancer.
Stroke
Association between the Thr325Ile polymorphism of the thrombin-activatable fibrinolysis inhibitor and stroke in the Ludwigshafen Risk and Cardiovascular Health Study.
Stroke
Carboxypeptidase U (TAFIa) decreases the efficacy of thrombolytic therapy in ischemic stroke patients.
Stroke
Dose-Response Relationship Between Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) and Stroke: A Chinese Case-Control Study.
Stroke
Haemostatic biomarkers are associated with long-term recurrent vascular events after ischaemic stroke.
Stroke
Phosphinanes and Azaphosphinanes as Potent and Selective Inhibitors of Activated Thrombin-Activatable Fibrinolysis Inhibitor (TAFIa).
Stroke
Procarboxypeptidase U (proCPU, TAFI, proCPB2) in cerebrospinal fluid during ischemic stroke is associated with stroke progression, outcome and blood-brain barrier dysfunction.
Stroke
Selective inhibition of carboxypeptidase U may reduce microvascular thrombosis in rat experimental stroke.
Stroke
The decrease in procarboxypeptidase U (TAFI) concentration in acute ischemic stroke correlates with stroke severity, evolution and outcome.
Stroke
Thrombin activatable fibrinolysis inhibitor gene polymorphisms are associated with antigenic levels in the Asian-Indian population but may not be a risk for stroke.
Stroke, Lacunar
Evaluation of platelet activation, coagulation, and fibrinolytic activation in patients with symptomatic lacunar stroke.
Thrombocytopenia
In vitro evaluation of clot quality and stability in a model of severe thrombocytopenia: effect of fibrinogen, factor XIII and thrombin-activatable fibrinolysis inhibitor.
Thrombocytopenia
Platelet Drop and Fibrinolytic Shutdown in Patients With Sepsis.
Thrombocytosis
Plasma levels of thrombin-activatable fibrinolysis inhibitor in primary and secondary thrombocytosis.
Thromboembolism
Absolute risk of venous and arterial thromboembolism in thrombophilic families is not increased by high thrombin-activatable fibrinolysis inhibitor (TAFI) levels.
Thromboembolism
S62798, a potent TAFIa inhibitor, accelerates endogenous fibrinolysis in a murine model of pulmonary thromboembolism.
Thromboembolism
Single nucleotide polymorphisms in an intergenic chromosome 2q region associated with tissue factor pathway inhibitor plasma levels and venous thromboembolism.
Thromboembolism
Tissue-type plasminogen activator transgenic rats for evaluating inhibitors of the activated form of thrombin-activatable fibrinolysis inhibitor.
Thrombophilia
Hemostasis in Overt and Subclinical Hyperthyroidism.
Thrombophilia
Preeclampsia and its interaction with common variants in thrombophilia genes.
Thrombophilia
Procarboxypeptidase U (TAFI) contributes to the risk of thrombosis in patients with hereditary thrombophilia.
Thrombophilia
Risk of early recurrent fetal loss and levels of thrombin-activatable fibrinolysis inhibitor.
Thrombophilia
Thromboembolism--an important manifestation of inflammatory bowel disease.
Thrombosis
A novel inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa) - part II: enhancement of both exogenous and endogenous fibrinolysis in animal models of thrombosis.
Thrombosis
Absolute risk of venous and arterial thromboembolism in thrombophilic families is not increased by high thrombin-activatable fibrinolysis inhibitor (TAFI) levels.
Thrombosis
Activated TAFI Promotes the Development of Chronic Thromboembolic Pulmonary Hypertension: A Possible Novel Therapeutic Target.
Thrombosis
Carboxypeptidase B2 and carboxypeptidase N in the crosstalk between coagulation, thrombosis, inflammation, and innate immunity.
Thrombosis
Changes in coagulation-fibrinolysis balance in blood mononuclear cells and in gastric mucosa from patients with Helicobacter pylori infection.
Thrombosis
Crystal structures of TAFI elucidate the inactivation mechanism of activated TAFI: a novel mechanism for enzyme autoregulation.
Thrombosis
Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis.
Thrombosis
Discovery of novel mechanisms and molecular targets for the inhibition of activated thrombin activatable fibrinolysis inhibitor.
Thrombosis
Discovery of potent & selective inhibitors of activated thrombin-activatable fibrinolysis inhibitor for the treatment of thrombosis.
Thrombosis
Fenofibrate improves endothelial function and decreases thrombin-activatable fibrinolysis inhibitor concentration in metabolic syndrome.
Thrombosis
Fibrinolysis and the risk of venous and arterial thrombosis.
Thrombosis
Genetic Polymorphisms Associated with Thrombotic Disease Comparison of Two Territories: Myocardial Infarction and Ischemic Stroke.
Thrombosis
Genetic variation in thrombin-activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis.
Thrombosis
Haplotypes of TAFI gene and the risk of cerebral venous thrombosis--a case-control study.
Thrombosis
High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke.
Thrombosis
Inhibition of carboxypeptidase U (TAFIa) activity improves rt-PA induced thrombolysis in a dog model of coronary artery thrombosis.
Thrombosis
Inside the Thrombus: Association of Hemostatic Parameters With Outcomes in Large Vessel Stroke Patients.
Thrombosis
Isolation, Co-Crystallization and Structure-Based Characterization of Anabaenopeptins as Highly Potent Inhibitors of Activated Thrombin Activatable Fibrinolysis Inhibitor (TAFIa).
Thrombosis
Levels of thrombin-activatable fibrinolysis inhibitor and platelet-activating factor in recurrent pregnancy loss patients.
Thrombosis
Local proCPU (TAFI) activation during thrombolytic treatment in a dog model of coronary artery thrombosis can be inhibited with a direct, small molecule thrombin inhibitor (melagatran).
Thrombosis
Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men.
Thrombosis
Measurement of procarboxypeptidase U (TAFI) in human plasma: a laboratory challenge.
Thrombosis
Measuring fibrinolysis: from research to routine diagnostic assays.
Thrombosis
Mechanical circulatory device thrombosis: a new paradigm linking hypercoagulation and hypofibrinolysis.
Thrombosis
Murine model of ferric chloride-induced vena cava thrombosis: evidence for effect of potato carboxypeptidase inhibitor.
Thrombosis
Oxygenated analogues of UK-396082 as inhibitors of activated thrombin activatable fibrinolysis inhibitor.
Thrombosis
Plasma carboxypeptidases as regulators of the plasminogen system.
Thrombosis
Plasma levels of carboxypeptidase U (CPU, CPB2 or TAFIa) are elevated in patients with acute myocardial infarction.
Thrombosis
Procarboxypeptidase U (TAFI) contributes to the risk of thrombosis in patients with hereditary thrombophilia.
Thrombosis
Reduced thrombin activatable fibrinolysis inhibitor and enhanced inflammatory markers in ACS.
Thrombosis
Selective inhibition of carboxypeptidase U may reduce microvascular thrombosis in rat experimental stroke.
Thrombosis
Simvastatin treatment improves endothelial function and increases fibrinolysis in patients with hypercholestrolemia.
Thrombosis
TAFIa inhibitors in the treatment of thrombosis.
Thrombosis
TAFIa, PAI-1 and alpha-antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots.
Thrombosis
The Crystal Structure of Thrombin-activable Fibrinolysis Inhibitor (TAFI) Provides the Structural Basis for Its Intrinsic Activity and the Short Half-life of TAFIa.
Thrombosis
The plasma levels of activated thrombin activatable fibrinolysis inhibitor and thrombomodulin in Behçet disease and their association with thrombosis.
Thrombosis
The Prothrombotic State Associated with SARS-CoV-2 Infection: Pathophysiological Aspects.
Thrombosis
The role of thrombin activatable fibrinolysis inhibitor (TAFI) in arterial thrombosis at young age: the ATTAC study.
Thrombosis
Thrombin activatable fibrinolysis inhibitor (TAFI) - A possible link between coagulation and complement activation in the antiphospholipid syndrome (APS).
Thrombosis
Thrombin activatable fibrinolysis inhibitor and clot lysis time in pregnant patients with antiphospholipid syndrome: relationship with pregnancy outcome and thrombosis.
Thrombosis
Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis.
Thrombosis
Thrombin activatable fibrinolysis inhibitor in Behçet's disease.
Thrombosis
Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice are susceptible to intracerebral thrombosis and ischemic stroke.
Thrombosis
Thrombin-activatable fibrinolysis inhibitor activity in healthy and diseased dogs.
Thrombosis
Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation.
Thrombosis
Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI.
Thrombosis
Tissue-type plasminogen activator transgenic rats for evaluating inhibitors of the activated form of thrombin-activatable fibrinolysis inhibitor.
Thrombotic Microangiopathies
Association of genotypes of thrombin-activatable fibrinolysis inhibitors with thrombotic microangiopathies--a pilot study.
Thyroid Nodule
Effect of levothyroxine suppression therapy on plasma thrombin activatable fibrinolysis inhibitor antigen levels in benign thyroid nodules.
Venous Thromboembolism
Active PAI-1 as marker for venous thromboembolism: case-control study using a comprehensive panel of PAI-1 and TAFI assays.
Venous Thromboembolism
Carboxypeptidase B2 gene polymorphisms and the risk of venous thromboembolism.
Venous Thromboembolism
Co-segregation of thrombophilic disorders in factor V Leiden carriers; the contributions of factor VIII, factor XI, thrombin activatable fibrinolysis inhibitor and lipoprotein(a) to the absolute risk of venous thromboembolism.
Venous Thromboembolism
Impact of genetic polymorphisms in thrombin activatable fibrinolysis inhibitor (TAFI) on venous thrombosis disease: A meta-analysis.
Venous Thromboembolism
Safety and Pharmacokinetics of DS-1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin.
Venous Thromboembolism
Single nucleotide polymorphisms in an intergenic chromosome 2q region associated with tissue factor pathway inhibitor plasma levels and venous thromboembolism.
Venous Thromboembolism
Thrombin Activatable Fibrinolysis inhibitor in Cancer Patients with and without Venous Thromboembolism.
Venous Thromboembolism
Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism.
Venous Thromboembolism
[Correlation analysis of Thrombin-activatable Fibrinolysis Inhibitor Single Nucleotide Polymorphism with Venous Thromboembolism].
Venous Thrombosis
Association between thrombin-activatable fibrinolysis inhibitor gene polymorphisms and venous thrombosis risk: a meta-analysis.
Venous Thrombosis
Changes in ADMA and TAFI levels after stenting in coronary artery disease patients.
Venous Thrombosis
Decreased Plasma Fibrinolytic Potential As a Risk for Venous and Arterial Thrombosis.
Venous Thrombosis
Fibrinolysis and the risk of venous and arterial thrombosis.
Venous Thrombosis
Impact of genetic polymorphisms in thrombin activatable fibrinolysis inhibitor (TAFI) on venous thrombosis disease: A meta-analysis.
Venous Thrombosis
Insights into thrombin activatable fibrinolysis inhibitor function and regulation.
Venous Thrombosis
Murine model of ferric chloride-induced vena cava thrombosis: evidence for effect of potato carboxypeptidase inhibitor.
Venous Thrombosis
Phosphinanes and Azaphosphinanes as Potent and Selective Inhibitors of Activated Thrombin-Activatable Fibrinolysis Inhibitor (TAFIa).
Venous Thrombosis
Risk of cerebral venous thrombosis and novel gene polymorphisms of the coagulation and fibrinolytic systems.
Venous Thrombosis
S62798, a potent TAFIa inhibitor, accelerates endogenous fibrinolysis in a murine model of pulmonary thromboembolism.
Venous Thrombosis
Sex-specific effect of CPB2 Ala147Thr but not Thr325Ile variants on the risk of venous thrombosis: A comprehensive meta-analysis.
Venous Thrombosis
The effect of genetic variants in the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI-antigen levels, clot lysis time and the risk of venous thrombosis.
Venous Thrombosis
The impact of the fibrinolytic system on the risk of venous and arterial thrombosis.
Venous Thrombosis
Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis.
Venous Thrombosis
Thrombin-Activatable Fibrinolysis Inhibitor Polymorphisms and Cerebral Venous Thrombosis in Mexican Mestizo Patients.
Venous Thrombosis
Tissue-type plasminogen activator transgenic rats for evaluating inhibitors of the activated form of thrombin-activatable fibrinolysis inhibitor.
von Willebrand Diseases
Thrombotic and Hemorrhagic Conditions Due to a Gain of Function of Coagulation Proteins: A Special Type of Clotting Disorders.
Yersinia Infections
Protective Roles for Fibrin, Tissue Factor, Plasminogen Activator Inhibitor-1, and Thrombin Activatable Fibrinolysis Inhibitor, but Not Factor XI, during Defense against the Gram-Negative Bacterium Yersinia enterocolitica.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
A505G
-
naturally occurring polymorphism
A93V
-
mutant is comparably to wild-type activated by thrombin, mutant is slightly less activated by thrombin in the presence of thrombomodulin, kcat (1/sec) (p-anisylazoformyl-L-arginine, activated by thrombin in the presence of thrombomodulin): 0.205, Km (mM) (p-anisylazoformyl-L-arginine, activated by thrombin in the presence of thrombomodulin): 0.000169, mutation shows no effect on the activation by plasmin, kcat (1/sec) (hippuryl-arginine, activated by plasmin): 0.00043, Km (mM) (hippuryl-arginine, activated by plasmin): 0.00001, intrinsic stability of activated TAFI (half-life): 6.3 min
D87A
-
activated with similar kinetics as wild-type enzyme by thrombin-thrombomodulin. Increase in activation by plasmin. Thermal inactivation at 37°C is similar to that of the wild-type enzyme
I182R
-
site-directed mutagenesis, the mutant shows reduced activition by thrombin but similar fibrinogen and plasminogen binding capacitiy compared to the wild-type enzyme
I183E
-
site-directed mutagenesis, the mutant shows reduced activition by thrombin but similar fibrinogen and plasminogen binding capacitiy compared to the wild-type enzyme
I325I
-
a higher frequency of the most stable Ile325Ile proCPU is seen among carriers of FII G20210A mutation compared to the control group in comparison to Thr325Thr and Thr325Ile proCPU. In addition, proCPU as a risk factor for thrombosis is evaluated. In heterozygous carriers of FV Leiden or FII G20210A high levels of proCPU confers to an almost 4fold increased risk for spontaneous onset thrombosis. The more stable Ile325Ile proCPU seems to impose a higher risk for clinical manifestation of the thrombophilic condition
S305C/T329I
-
generation of a stable activated thrombin activable fibrinolysis inhibitor variant by site-directed mutagenesis, the mutant's half-life is 11fold increased compared to the wild-type enzyme, the mutant also shows about 3fold higher fibrin clot lysis activityoverview
S90A
-
activated with similar kinetics as wild-type enzyme by thrombin-thrombomodulin. Increase in activation by plasmin. Thermal inactivation at 37°C is similar to that of the wild-type enzyme
S90D/S94V/S90D
-
mutant is not activated by thrombin or by thrombin in the presence of thrombomodulin, mutant is weakly activated by plasmin, kcat (1/sec) (hippuryl-arginine, activated by plasmin): 0.00004, Km (mM) (hippuryl-arginine, activated by plasmin): 0.000005, intrinsic stability of activated TAFI (half-life): 5.9 min
S94V
-
mutant is considerably more effectively activated by thrombin, mutant is also activated by thrombin in the presence of thrombomodulin, kcat (1/sec) (p-anisylazoformyl-L-arginine, activated by thrombin in the presence of thrombomodulin): 0.328, Km (mM) (p-anisylazoformyl-L-arginine, activated by thrombin in the presence of thrombomodulin): 0.000232, mutation shows no effect on the activation by plasmin, kcat (1/sec) (hippuryl-arginine, activated by plasmin): 0.0003, Km (mM) (hippuryl-arginine, activated by plasmin): 0.000006, intrinsic stability of activated TAFI (half-life): 6.1 min
T147A
-
naturally occurring polymorphism
T325I/T329I/H333Y/H335Q
-
inactive mutant has a 70fold increased half-life and a 3fold to 5fold increased antifibrinolytic function as compared to wild-type, mutant aggregates into large, insoluble complexes that can be removed by centrifugation
P91S
-
mutant exhibits specific impairment of activation by thrombin or thrombin-TM, thrombin alone, and thrombin alone or plasmin, respectively
P91S
-
mutant is not activated by thrombin or by thrombin in the presence of thrombomodulin, mutant is weakly activated by plasmin, kcat (1/sec) (hippuryl-arginine, activated by plasmin): 0.00020, Km (mM) (hippuryl-arginine, activated by plasmin): 0.000007, intrinsic stability of activated TAFI (half-life): 6.3 min
R302Q
-
specific activity with hippuryl-Arg is approximately half that of either recombinant wild-type enzyme or plasma derived enzymeR302Q-TAFIa is not proteolyzed by thrombin, even when 10times higher concentrations of thrombin/thrombomodulin are used
R302Q
-
mutant aggregates similarly to wild-type protein
R92K
-
mutant exhibits specific impairment of activation by thrombin or thrombin-TM, thrombin alone, and thrombin alone or plasmin, respectively
R92K
-
mutant is not activated by thrombin, mutant is very efficiently activated by thrombin in the presence of thrombomodulin, kcat (1/sec) (p-anisylazoformyl-L-arginine, activated by thrombin in the presence of thrombomodulin): 0.215, Km (mM) (p-anisylazoformyl-L-arginine, activated by thrombin in the presence of thrombomodulin): 0.000229, mutant is activated by plasmin with similar kinetics as wild-type, kcat (1/sec) (hippuryl-arginine, activated by plasmin): 0.00039, Km (mM) (hippuryl-arginine, activated by plasmin): 0.000006, intrinsic stability of activated TAFI (half-life): 7.1 min
S90P
-
mutant exhibits specific impairment of activation by thrombin or thrombin-TM, thrombin alone, and thrombin alone or plasmin, respectively
S90P
-
mutant is not activated by thrombin, mutant is very efficiently activated by thrombin in the presence of thrombomodulin, kcat (1/sec) (p-anisylazoformyl-L-arginine, activated by thrombin in the presence of thrombomodulin): 0.377, Km (mM) (p-anisylazoformyl-L-arginine, activated by thrombin in the presence of thrombomodulin): 0.000162, mutant is weakly activated by plasmin, kcat (1/sec) (hippuryl-arginine, activated by plasmin): 0.00008, Km (mM) (hippuryl-arginine, activated by plasmin): 0.000009, intrinsic stability of activated TAFI (half-life): 5.5 min
T325I
-
naturally occurring mutant showing a twofold increased stability compared to the wild-type enzyme
T325I
-
naturally occurring polymorphism
T325I
-
distribution of the Thr325Ile proCPU polymorphism in 193 patients with mucocutaneous bleeding of whom 116 are bleeders of unknown cause , and in 143 healthy, age and sex-matched controls is analyzed. ProCPU concentration is higher in women than in men, increases with age, and is significantly correlated with clot lysis time, platelet count, APTT, and PT. proCPU levels are unexpectedly higher in patients than in controls. The allele distribution of the Thr325Ile proCPU polymorphism is similar in both groups, with a low percentage of homozygous Ile/Ile
additional information
immobilization of purified recombinnat Pro-CPU on Sepharose for specific antibody purification
additional information
-
immobilization of purified recombinnat Pro-CPU on Sepharose for specific antibody purification
additional information
-
generation of a TAFI a form with a highly stable activity by replacing a region in TAFI with the corresponding region in pancreatic CPB (carboxypeptidase B). TAFI-CPB(293-333) can be activated by thrombin-thrombomodulin, but not as efficient as wild-type TAFI. After activation, this chimeric enzyme is unstable and hardly able to prolong clot lysis of TAFI-deficient plasma. Binding of the mutant enzyme to both plasminogen and fibrinogen is normal compared to wild-type TAFI. TAFI-CPB(293-401) can be activated by thrombin-thrombomodulin, although at a lower rate compared with wild-type TAFI. The activated mutant displays a markedly prolonged half-life of 1.5 h. The chimeric enzyme does not bind plasminogen and fibrinogen and can prolong the clot lysis time in TAFI-deficient plasma, although not as efficiently as wild-type TAFI
additional information
-
mutant with the fibrinogen Bbeta thrombin cleavage site Ala-Arg-Gly-His-Arg substituted into positions 91-95: activated with similar kinetics as wild-type enzyme by thrombin-thrombomodulin, activated by plasmin with the same kinetics as wild-type enzyme. Mutant enzyme with the protein C thrombin cleavage site Asp-Pro-Arg-Leu-Ile-Asp substituted into positions 90-95: no measurable activation by plasmin
additional information
-
construction of chimeric proteins composed by wild-type TAFI isozymes Thr147 and Thr325, and carboxypeptidase B, CPB, fragments comprising residues 288-395 and 288-327, the chimeric mutants show increase stability and 32-34fold increased half-lives compared to the wild-type TAFI
additional information
-
enzyme disorder phenotype, overview
additional information
-
the enzyme shows polymorphisms, e.g. at residue 325, genotypes, correlated diseases, overview
additional information
-
circulating TAFI levels and carotid intima-media thickness (CIMT) in polycystic ovary syndrome (PCOS) patients and control subjects are analysed. Plasma TAFI levels are similarly in polycystic ovary syndrome patients compared with healthy controls. No difference is observed in the combined IMT among the studied groups
additional information
-
coagulation and fibrinolytic parameters including TAFI and TFPI are assessed in patients with hypothyroidism: Factors V, VII, VIII activities, von Willebrand factor, protein C, protein S, thrombomodulin, TFPI, and TAFI are measured. Compared with the control subjects, factor VII activity, and thrombomodulin Ag and TAFI Ag levels are significantly increased in patients with hypothyroidism, whereas FV, FVIII, vWF, protein C and protein S activities, and TFPI Ag levels are significantly decreased
additional information
-
HT1080 cells mediate activation of TAFI in plasma in the presence of soluble-type thrombomodulin through cell-dependent prothrombin activation. HT1080 cells stably expressing thrombomodulin (TM-HT1080) mediate plasma TAFI activation without added soluble-type thrombomodulin, wild-type cells and Mock-transfected HT1080 cells (Mock) do not. Production of TAFIa suppresses cell-mediated plasminogen activation. Cell invasion by TMHT1080 is partially enhanced by addition of a TAFIa/CPB inhibitor
additional information
-
plasma TAFI and PAI-1 antigen levels are measured in pregnant women with gestational diabetes, pregnant women with normal glucose tolerance, and age-matched non-pregnant women with no history of gestational diabetes. Increased plasma TAFI antigen levels are found in pregnant women compared to non-pregnant controls. No statistically significant difference in TAFI antigen levels is observed between women with gestational diabetes and pregnant controls. Plasma PAI-1 antigen levels are higher in gestational diabetes than pregnant and non-pregnant controls
additional information
-
proCPU levels in thrombophilia carriers and healthy subjects are assessed: Results show that patients with inherited thrombophilia have a tendency toward lower mean proCPU plasma levels compared to healthy controls. This difference is only significant in carriers of factor II G20210A
additional information
-
TAFI activity status and the effect of L-thyroxin hormone replacement treatment on fibrinolytic system in patients with Hashimotos thyroiditis is analysed: In the control group, TAFI activity levels are 9.6 microgram/ml. In patients with L-thyroxin before and after treatment there are high levels of TAFI activity value of 14.2 and 12.9 microgram/ml, respectively. In the patient group, after L-thyroxin treatment TAFI activity levels are decreased but they are not statistically significant. When compared to the control group, high levels of TAFI activity are observed in the patient group
additional information
-
the gastric intramucosal concentrations of TAFI are measured by enzyme immunoassay. This study comprises 65 patients with gastroduodenal disorders. The gastric levels of TAFI and plasminogen activator inhibitor-1 are significantly increased in patients with Helicobacter pylori compared to those without infection or cured Helicobacter pylori
additional information
-
the levels of TAFI antigen and also its relationship with other hemostasis markers in a group of patients affected with polycystic ovary syndrome (PCOS)-under Diane-35 (ethinyl estradiol/cyproterone acetate) treatment or not compared with a group of healthy controls is analysed. TAFI antigen levels of groups A and B are significantly higher than in controls, but no difference is observed between them. All of the other coagulation and fibrinolysis parameters are comparable between the three groups
additional information
-
variant mutants are constructed and expressed mutant variants that have key substitutions in the amino acids surrounding the scissile Arg92-Ala93 bond. Variants are identified that show patterns of resistance to specific activators. The variants that are tested also showed antifibrinolytic potentials that can be rationalized in terms of which enzymes are capable of activating them
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Bajazar, L.; Nesheim, M.; Morser, J.; Tracy, P.B.
Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activable fibrinolysis inhibitor
J. Biol. Chem.
273
2792-2798
1998
Homo sapiens
brenda
Boffa, M.B.; Wang, W.; Bajzar, l.; Nesheim, M.E.
Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respsct to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties
J. Biol. Chem.
273
2127-2135
1998
Homo sapiens
brenda
Kokame, K.; Zheng, X.; Sadler, J.E.
Activation of thrombin-activable fibrinolysis inhibitor requires epidermal growth factor-like domain 3 of thrombomodulin and is inhibited competitively by protein C
J. Biol. Chem.
273
12135-12139
1998
Homo sapiens
brenda
Cote, H.; Bajzar, L.; Stevens, W.K.; Samis, J.A.; Morser, J.; MacGillivray, R.T.A.; Nesheim, M.E.
Functional characterization of recombinant human meizothrombin and meizothrombin (desF1)
J. Biol. Chem.
272
6194-6200
1997
Homo sapiens
brenda
Sakharov, D.V.; Plow, E.F.; Rijken, D.C.
On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B
J. Biol. Chem.
272
14477-14482
1997
Homo sapiens
brenda
Nesheim, M.; Wang, W.; Boffa, M.; Nagashima, M.; Morser, J.; Bajzar, L.
Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis
Thromb. Haemost.
78
386-391
1997
Homo sapiens
brenda
Von dem Borne, P.A.K.; Bajzar, L.; Meijers, J.C.M.; Nesheim, M.E.; Bouma, B.N.
Thrombin-mediated activation of factor XI results in a thrombin-activable fibrinolysis inhibitor-dependent inhibition of fibrinolysis
J. Clin. Invest.
99
2323-2327
1997
Homo sapiens
brenda
Broze, G.J.
Thrombin-dependent inhibition of fibrinolysis
Curr. Opin. Hematol.
3
390-394
1996
Homo sapiens
brenda
Bajzar, L.; Morser, J.; Nesheim, M.
TAFI, or plasma procarboxypeptidase B couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex
J. Biol. Chem.
271
16603-16608
1996
Homo sapiens
brenda
Broze, G.J.; Higuchi, D.A.
Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hepatitis plasma
Blood
88
3815-3823
1996
Homo sapiens
brenda
Tan, A.K.; Eaton, D.L.
Activation and characterization of procarboxypeptidase B from human plasma
Biochemistry
34
5811-5816
1995
Homo sapiens
brenda
Bajzar, L.; Manuel, R.; Nesheim, M.E.
Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor
J. Biol. Chem.
270
14477-14484
1995
Homo sapiens
brenda
Wang, W.; Hendricks, D.F.; Scharpe, S.S.
Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen
J. Biol. Chem.
269
15937-15944
1994
Homo sapiens
brenda
Eaton, D.L.; Malloy, B.E.; Tsai, S.P.; Henzel, W.; Drayna, D.
Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma
J. Biol. Chem.
266
21833-21838
1991
Homo sapiens
brenda
Kawamura, T.; Okada, N.; Okada, H.
Elastase from activated human neutrophils activates procarboxypeptidase R
Microbiol. Immunol.
46
225-230
2002
Homo sapiens
brenda
Mao, S.S.; Colussi, D.; Bailey, C.M.; Bosserman, M.; Burlein, C.; Gardell, S.J.; Carroll, S.S.
Electrochemiluminescence assay for basic carboxypeptidases: inhibition of basic carboxypeptidases and activation of thrombin-activatable fibrinolysis inhibitor
Anal. Biochem.
319
159-170
2003
Chlorocebus aethiops, Canis lupus familiaris, Homo sapiens, Macaca mulatta, Rattus norvegicus
brenda
Lazoura, E.; Campbell, W.; Yamaguchi, Y.; Kato, K.; Okada, N.; Okada, H.
Rational structure-based design of a novel carboxypeptidase R inhibitor
Chem. Biol.
9
1129-1139
2002
Homo sapiens
brenda
Marx, P.F.; Hackeng, T.M.; Dawson, P.E.; Griffin, J.H.; Meijers, J.C.; Bouma, B.N.
Inactivation of active thrombin-activable fibrinolysis inhibitor takes place by a process that involves conformational instability rather than proteolytic cleavage
J. Biol. Chem.
275
12410-12415
2000
Homo sapiens
brenda
Schneider, M.; Nagashima, M.; Knappe, S.; Zhao, L.; Morser, J.; Nesheim, M.
Amino acid residues in the P6-P'3 region of thrombin-activable fibrinolysis inhibitor (TAFI) do not determine the thrombomodulin dependence of TAFI activation
J. Biol. Chem.
277
9944-9951
2002
Homo sapiens
brenda
Marx, P.F.; Havik, S.R.; Marquart, J.A.; Bouma, B.N.; Meijers, J.C.
Generation and characterization of a highly stable form of activated thrombin-activable fibrinolysis inhibitor
J. Biol. Chem.
279
6620-6628
2004
Homo sapiens
brenda
Suzuki, K.; Muto, Y.; Fushihara, K.; Kanemoto, K.; Iida, H.; Sato, E.; Kikuchi, C.; Matsushima, T.; Kato, E.; Nomoto, M.; Yoshioka, S.; Ishii, H.
Enhancement of fibrinolysis by EF6265 [(S)-7-amino-2-[[[(R)-2-methyl-1-(3-phenylpropanoylamino)propyl]hydroxypho sphinoyl] methyl]heptanoic acid], a specific inhibitor of plasma carboxypeptidase B
J. Pharmacol. Exp. Ther.
309
607-615
2004
Homo sapiens, Rattus norvegicus
brenda
Campbell, W.D.; Lazoura, E.; Okada, N.; Okada, H.
Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N
Microbiol. Immunol.
46
131-134
2002
Homo sapiens
brenda
Komura, H.; Shimomura, Y.; Yumoto, M.; Katsuya, H.; Okada, N.; Okada, H.
Heat stability of carboxypeptidase R of experimental animals
Microbiol. Immunol.
46
217-223
2002
Cavia porcellus, Homo sapiens, Oryctolagus cuniculus, Rattus norvegicus
brenda
Bouma, B.N.; Marx, P.F.; Mosnier, L.O.; Meijers, J.C.
Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U)
Thromb. Res.
101
329-354
2001
Papio sp., Canis lupus familiaris, Cavia porcellus, Oryctolagus cuniculus, Homo sapiens, Mus musculus, Rattus norvegicus, Sus scrofa
brenda
Valnickova, Z.; Christensen, T.; Skottrup, P.; Th?gersen, I.B.; H?jrup, P.; Enghild, J.J.
Post-translational modifications of human thrombin-activatable fibrinolysis inhibitor (TAFI): evidence for a large shift in the isoelectric point and reduced solubility upon activation
Biochemistry
45
1525-1535
2006
Homo sapiens (Q96IY4), Homo sapiens
brenda
Polla, M.O.; Tottie, L.; Norden, C.; Linschoten, M.; Muesil, D.; Trumpp-Kallmeyer, S.; Aukrust, I.R.; Ringom, R.; Holm, K.H.; Neset, S.M.; Sandberg, M.; Thurmond, J.; Yu, P.; Hategan, G.; Anderson, H.
Design and synthesis of potent, orally active, inhibitors of carboxypeptidase U (TAFIa)
Bioorg. Med. Chem.
12
1151-1175
2004
Homo sapiens
brenda
Willemse, J.L.; Hendriks, D.F.
Measurement of procarboxypeptidase U (TAFI) in human plasma: a laboratory challenge
Clin. Chem.
52
30-36
2006
Homo sapiens
brenda
Stroemqvist, M.; Hansson, L.; Andersson, J.O.; Johansson, T.; Edlund, M.; Enoksson, M.; Goossens, F.; Scharpe, S.; Hendriks, D.
Properties of recombinant human plasma procarboxypeptidase U produced in mammalian and insect cells
Clin. Chim. Acta
347
49-59
2004
Homo sapiens (Q96IY4), Homo sapiens
brenda
Marx, P.F.
Thrombin-activatable fibrinolysis inhibitor
Curr. Med. Chem.
11
2335-2348
2004
Homo sapiens, Mus musculus
brenda
Ceresa, E.; Van de Borne, K.; Peeters, M.; Lijnen, H.R.; Declerck, P.J.; Gils, A.
Generation of a stable activated thrombin activable fibrinolysis inhibitor variant
J. Biol. Chem.
281
15878-15883
2006
Homo sapiens
brenda
Marx P. , M.P.; Meijers J. C. , M.J.
Mechanism of action of carboxypeptidase U: staying above the threshold
J. Thromb. Haemost.
2
414-415
2004
Homo sapiens
brenda
Guimaraes, A.H.; Bertina, R.M.; Rijken, D.C.
A new functional assay of thrombin activatable fibrinolysis inhibitor
J. Thromb. Haemost.
3
1284-1292
2005
Homo sapiens
brenda
Marx, P.F.; Havik, S.R.; Bouma, B.N.; Meijers, J.C.
Role of isoleucine residues 182 and 183 in thrombin-activatable fibrinolysis inhibitor
J. Thromb. Haemost.
3
1293-1300
2005
Homo sapiens
brenda
Willemse, J.L.; Leurs, J.R.; Hendriks, D.F.
Fast kinetic assay for the determination of procarboxypeptidase U in human plasma
J. Thromb. Haemost.
3
2353-2355
2005
Homo sapiens
brenda
Matthews, K.W.; Mueller-Ortiz, S.L.; Wetsel, R.A.
Carboxypeptidase N: a pleiotropic regulator of inflammation
Mol. Immunol.
40
785-793
2004
Homo sapiens
brenda
Borgstroem, A.; Regner, S.
Active carboxypeptidase B is present in free form in serum from patients with acute pancreatitis
Pancreatology
5
530-536
2005
Homo sapiens
brenda
Bouma, B.N.; Mosnier, L.O.
Thrombin activatable fibrinolysis inhibitor (TAFI) at the interface between coagulation and fibrinolysis
Pathophysiol. Haemost. Thromb.
33
375-381
2005
Homo sapiens, Mus musculus
brenda
Bouma, B.N.; Meijers, J.C.
New insights into factors affecting clot stability: A role for thrombin activatable fibrinolysis inhibitor (TAFI; plasma procarboxypeptidase B, plasma procarboxypeptidase U, procarboxypeptidase R)
Semin. Hematol.
41 Suppl 1
13-19
2004
Homo sapiens
brenda
Mousa, H.A.; Downey, C.; Alfirevic, Z.; Toh, C.H.
Thrombin activatable fibrinolysis inhibitor and its fibrinolytic effect in normal pregnancy
Thromb. Haemost.
92
1025-1031
2004
Homo sapiens
brenda
Frere, C.; Morange, P.E.; Saut, N.; Tregouet, D.A.; Grosley, M.; Beltran, J.; Juhan-Vague, I.; Alessi, M.C.
Quantification of thrombin activatable fibrinolysis inhibitor (TAFI) gene polymorphism effects on plasma levels of TAFI measured with assays insensitive to isoform-dependent artefact
Thromb. Haemost.
94
373-379
2005
Homo sapiens
brenda
Leurs, J.; Hendriks, D.
Carboxypeptidase U (TAFIa): a metallocarboxypeptidase with a distinct role in haemostasis and a possible risk factor for thrombotic disease
Thromb. Haemost.
94
471-487
2005
Homo sapiens
brenda
Donmez, A.; Aksu, K.; Celik, H.A.; Keser, G.; Cagirgan, S.; Omay, S.B.; Inal, V.; Aydin, H.H.; Tombuloglu, M.; Doganavsargil, E.
Thrombin activatable fibrinolysis inhibitor in Behcets disease
Thromb. Res.
115
287-292
2005
Homo sapiens
brenda
Do, Y.H.; Gifford-Moore, D.S.; Beight, D.W.; Rathnachalam, R.; Klimkowski, V.J.; Warshawsky, A.M.; Lu, D.
Inhibition of thrombin activatable fibrinolysis inhibitor by cysteine derivatives
Thromb. Res.
116
265-271
2005
Homo sapiens
brenda
Uszynski, W.; Uszynski, M.; Zekanowska, E.
Thrombin activatable fibrinolysis inhibitor (TAFI) in human amniotic fluid. A preliminary study
Thromb. Res.
119
241-245
2006
Homo sapiens
brenda
Higuchi, T.; Nakamura, T.; Kakutani, H.; Ishii, H.
Thrombomodulin suppresses invasiveness of HT1080 tumor cells by reducing plasminogen activation on the cell surface through activation of thrombin-activatable fibrinolysis inhibitor
Biol. Pharm. Bull.
32
179-185
2009
Homo sapiens
brenda
Nielsen, V.G.
Clot life span model analysis of clot growth and fibrinolysis in normal subjects: role of thrombin activatable fibrinolysis inhibitor
Blood Coagul. Fibrinolysis
19
283-287
2008
Homo sapiens
brenda
Kilicarslan, A.; Yavuz, B.; Guven, G.S.; Atalar, E.; Sahiner, L.; Beyazit, Y.; Kekilli, M.; Ozer, N.; Oz, G.; Haznedaroglu, I.C.; Sozen, T.
Fenofibrate improves endothelial function and decreases thrombin-activatable fibrinolysis inhibitor concentration in metabolic syndrome
Blood Coagul. Fibrinolysis
19
310-314
2008
Homo sapiens
brenda
Nielsen, V.G.; Kirklin, J.K.
Argatroban enhances fibrinolysis by differential inhibition of thrombin-mediated activation of thrombin activatable fibrinolysis inhibitor and factor XIII
Blood Coagul. Fibrinolysis
19
793-800
2008
Homo sapiens
brenda
Matus, V.; Willemse, J.; Quiroga, T.; Goycoolea, M.; Aranda, E.; Panes, O.; Pereira, J.; Hendriks, D.; Mezzano, D.
Procarboxypeptidase U (TAFI) and the Thr325Ile proCPU polymorphism in patients with hereditary mucocutaneous hemorrhages
Clin. Chim. Acta
401
158-161
2009
Homo sapiens
brenda
Koldas, M.; Gummus, M.; Seker, M.; Seval, H.; Hulya, K.; Dane, F.; Kural, A.; Gumus, A.; Salepci, T.; Turhal, N.S.
Thrombin-activatable fibrinolysis inhibitor levels in patients with non-small-cell lung cancer
Clin. Lung Cancer
9
112-115
2008
Homo sapiens (Q8IWV7), Homo sapiens
brenda
Brouns, R.; Heylen, E.; Sheorajpanday, R.; Willemse, J.L.; Kunnen, J.; De Surgeloose, D.; Hendriks, D.F.; De Deyn, P.P.
Carboxypeptidase U (TAFIa) decreases the efficacy of thrombolytic therapy in ischemic stroke patients
Clin. Neurol. Neurosurg.
111
165-170
2009
Homo sapiens
brenda
Akinci, B.; Demir, T.; Saygili, S.; Yener, S.; Alacacioglu, I.; Saygili, F.; Bayraktar, F.; Yesil, S.
Gestational diabetes has no additional effect on plasma thrombin-activatable fibrinolysis inhibitor antigen levels beyond pregnancy
Diabetes Res. Clin. Pract.
81
93-96
2008
Homo sapiens
brenda
Erem, C.; Ucuncu, O.; Yilmaz, M.; Kocak, M.; Nuhoglu, I.; Ersoz, H.O.
Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hypothyroidism
Endocrine
35
75-80
2009
Homo sapiens
brenda
Koutroubakis, I.E.; Sfiridaki, A.; Tsiolakidou, G.; Coucoutsi, C.; Theodoropoulou, A.; Kouroumalis, E.A.
Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease
Eur. J. Gastroenterol. Hepatol.
20
912-916
2008
Homo sapiens
brenda
Erdogan, M.; Karadeniz, M.; Alper, G.E.; Tamsel, S.; Uluer, H.; Caglayan, O.; Saygili, F.; Yilmaz, C.
Thrombin-activatable fibrinolysis inhibitor and cardiovascular risk factors in polycystic ovary syndrome
Exp. Clin. Endocrinol. Diabetes
116
143-147
2008
Homo sapiens
brenda
Karakurt, F.; Gumus, I.I.; Bavbek, N.; Kargili, A.; Koca, C.; Selcoki, Y.; Ozbek, M.; Kosar, A.; Akcay, A.
Increased thrombin-activatable fibrinolysis inhibitor antigen levels as a clue for prothrombotic state in polycystic ovary syndrome
Gynecol. Endocrinol.
24
491-497
2008
Homo sapiens
brenda
Ikeda, A.; Gabazza, E.C.; Morser, J.; Imoto, I.; Kuroda, M.; DAlessandro-Gabazza, C.N.; Hara, K.; Ruiz, D.B.; Bernabe, P.G.; Katsurahara, M.; Toda, M.; Kobayashi, Y.; Yano, Y.; Sumida, Y.; Suzuki, K.; Taguchi, O.; Takei, Y.
Presence of thrombin-activatable fibrinolysis inhibitor in Helicobacter pylori-associated gastroduodenal disease
Helicobacter
14
147-155
2009
Homo sapiens
brenda
Cetinkalp, S.; Tobu, M.; Karadeniz, M.; Buyukkececi, F.; Yilmaz, C.
The effect of hormone replacement treatment on thrombin-activatable fibrinolysis inhibitor activity levels in patients with Hashimoto thyroiditis
Intern. Med.
48
281-285
2009
Homo sapiens
brenda
Willemse, J.L.; Brouns, R.; Heylen, E.; De Deyn, P.P.; Hendriks, D.F.
Carboxypeptidase U (TAFIa) activity is induced in vivo in ischemic stroke patients receiving thrombolytic therapy
J. Thromb. Haemost.
6
200-202
2008
Homo sapiens
brenda
Marx, P.F.; Plug, T.; Havik, S.R.; Moergelin, M.; Meijers, J.C.
The activation peptide of thrombin-activatable fibrinolysis inhibitor: a role in activity and stability of the enzyme?
J. Thromb. Haemost.
7
445-452
2009
Homo sapiens
brenda
Foley, J.H.; Nesheim, M.E.
Soluble thrombomodulin partially corrects the premature lysis defect in FVIII-deficient plasma by stimulating the activation of thrombin activatable fibrinolysis inhibitor
J. Thromb. Haemost.
7
453-459
2009
Homo sapiens
brenda
Miah, M.F.; Boffa, M.B.
Functional analysis of mutant variants of thrombin-activatable fibrinolysis inhibitor resistant to activation by thrombin or plasmin
J. Thromb. Haemost.
7
665-672
2009
Homo sapiens
brenda
Sanglas, L.; Valnickova, Z.; Arolas, J.L.; Pallares, I.; Guevara, T.; Sola, M.; Kristensen, T.; Enghild, J.J.; Aviles, F.X.; Gomis-Rueth, F.X.
Structure of activated thrombin-activatable fibrinolysis inhibitor, a molecular link between coagulation and fibrinolysis
Mol. Cell
31
598-606
2008
Homo sapiens, Bos taurus (Q2KIG3), Bos taurus
brenda
Folkeringa, N.; Coppens, M.; Veeger, N.J.; Bom, V.J.; Middeldorp, S.; Hamulyak, K.; Prins, M.H.; Bueller, H.R.; van der Meer, J.
Absolute risk of venous and arterial thromboembolism in thrombophilic families is not increased by high thrombin-activatable fibrinolysis inhibitor (TAFI) levels
Thromb. Haemost.
100
38-44
2008
Homo sapiens
brenda
Heylen, E.; Miljic, P.; Willemse, J.; Djordjevic, V.; Radojkovic, D.; Colovic, M.; Elezovic, I.; Hendriks, D.
Procarboxypeptidase U (TAFI) contributes to the risk of thrombosis in patients with hereditary thrombophilia
Thromb. Res.
124
427-432
2009
Homo sapiens
brenda
Heylen, E.; Van Goethem, S.; Willemse, J.; Olsson, T.; Augustyns, K.; Hendriks, D.
Development of a sensitive and selective assay for the determination of procarboxypeptidase U (thrombin-activatable fibrinolysis inhibitor) in plasma
Anal. Biochem.
396
152-154
2010
Homo sapiens
brenda
Heylen, E.; Van Goethem, S.; Augustyns, K.; Hendriks, D.
Measurement of carboxypeptidase U (active thrombin-activatable fibrinolysis inhibitor) in plasma: Challenges overcome by a novel selective assay
Anal. Biochem.
403
114-116
2010
Homo sapiens
brenda
Fernandez, D.; Pallares, I.; Vendrell, J.; Aviles, F.X.
Progress in metallocarboxypeptidases and their small molecular weight inhibitors
Biochimie
93
1484-1500
2010
Homo sapiens
brenda
Willemse, J.L.; Heylen, E.; Nesheim, M.E.; Hendriks, D.F.
Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy?
J. Thromb. Haemost.
7
1962-1971
2009
Homo sapiens
brenda
Brouns, R.; Heylen, E.; Willemse, J.L.; Sheorajpanday, R.; De Surgeloose, D.; Verkerk, R.; De Deyn, P.P.; Hendriks, D.F.
The decrease in procarboxypeptidase U (TAFI) concentration in acute ischemic stroke correlates with stroke severity, evolution and outcome
J. Thromb. Haemost.
8
75-80
2010
Homo sapiens
brenda
Leenaerts, D.; Bosmans, J.M.; van der Veken, P.; Sim, Y.; Lambeir, A.M.; Hendriks, D.
Plasma levels of carboxypeptidase U (CPU, CPB2 or TAFIa) are elevated in patients with acute myocardial infarction
J. Thromb. Haemost.
13
2227-2232
2015
Homo sapiens (Q96IY4), Homo sapiens
brenda
Leenaerts, D.; Loyau, S.; Mertens, J.C.; Boisseau, W.; Michel, J.B.; Lambeir, A.M.; Jandrot-Perrus, M.; Hendriks, D.
Carboxypeptidase U (CPU, carboxypeptidase B2, activated thrombin-activatable fibrinolysis inhibitor) inhibition stimulates the fibrinolytic rate in different invitro models
J. Thromb. Haemost.
16
2057-2069
2018
Homo sapiens (Q96IY4)
brenda
Mertens, J.; Claesen, K.; Leenaerts, D.; Sim, Y.; Lambeir, A.; Hendriks, D.
Inhibition of the procarboxypeptidase U (proCPU, TAFI, proCPB2) system due to hemolysis
J. Thromb. Haemost.
17
878-884
2019
Homo sapiens (Q96IY4)
brenda
Leenaerts, D.; Aernouts, J.; Van Der Veken, P.; Sim, Y.; Lambeir, A.M.; Hendriks, D.
Plasma carboxypeptidase U (CPU, CPB2, TAFIa) generation during in vitro clot lysis and its interplay between coagulation and fibrinolysis
Thromb. Haemost.
117
1498-1508
2017
Homo sapiens (Q96IY4)
brenda